Primary Carnitine Deficiency
- PO (Adults ): Tablets: 990 mg 23 times daily. Oral solution: 1000 mg/day in divided doses (given every 34 hr throughout the day); titrate slowly as needed up to 3000 mg/day in divided doses (given every 34 hr throughout the day) based on tolerance and therapeutic response.
- PO (Children ): Tablets or solution: 50100 mg/kg/day in divided doses (given 24 times daily); may titrate slowly as needed based on serum carnitine concentrations to 100400 mg/kg/day (max dose = 3000 mg/day).
Secondary Carnitine Deficiency
- PO (Adults ): Tablets: 990 mg 23 times daily. Oral solution: 1000 mg/day in divided doses (given every 34 hr); titrate slowly as needed up to 3000 mg/day in divided doses (given every 34 hr) based on tolerance and therapeutic response.
- PO (Children ): Tablets or solution: 50100 mg/kg/day in divided doses (given 24 times daily); may titrate slowly as needed based on serum carnitine concentrations to 100400 mg/kg/day (max dose = 3000 mg/day).
- IV (Adults and Children ): 50 mg/kg/day in divided doses (given every 36 hr); subsequent doses of 50 mg/kg/day may be given if clinically indicated.
Carnitine Deficiency in Patients With End-Stage Renal Disease Requiring Hemodialysis.
- IV (Adults and Children ): 1020 mg/kg (using dry body weight) after each dialysis session; guide dosage adjustments by trough (predialysis) levocarnitine concentrations. Evaluate clinical response every 3 mo and titrate to the lowest effective dose; therapy should be discontinued if no improvement is seen after 912 mo of therapy.
Acute Valproic Acid Overdose/Toxicity (Off Label)
- IV (Adults ): 100 mg/kg initially; then 50 mg/kg (max dose = 3,000 mg) every 8 hr until serum ammonia concentrations begin to ↓ and clinical improvement occurs.
- IV (Children ): No evidence of hepatotoxicity: 25 mg/kg every 6 hr (max dose = 3000 mg/day ) until serum ammonia and valproic acid concentrations begin to ↓ and clinical improvement occurs. Symptomatic hyperammonemia or hepatotoxicity: 100 mg/kg (max dose = 6000 mg) initially; then 15 mg/kg every 46 hr until serum ammonia concentrations begin to ↓ and clinical improvement occurs.
Therapeutic Classification: none assigned
Absorption: 15% absorbed following oral administration. IV administration results in complete bioavailability.
Distribution: Unknown.
Metabolism/Excretion: Primarily metabolized in the liver to two active metabolites. Primarily excreted in the urine (76%; 48% as unchanged drug).
Half-Life: 17.4 hr.